BRAF and neoplasm: The CDC42SE2-BRAF fusion, found in both the original patient’s tumor and PDX represent a new type of BRAF fusion (type III), characterized by a complete loss of autoregulatory domain (exon 1–9) but preservation of kinase domain (exon 11–18) (Fig. 5F)44.